Cited by 305Craniofacial Disorders and TreatmentsBone Metabolism and DiseasesFibroblast Growth Factor Research

Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault

Iseki, S., Wilkie, A. O. M., Morriss-Kay, G. M.·1999·Development

Abstract

Fibroblast growth factor receptors (FGFRs) play major roles in skeletogenesis, and activating mutations of the human FGFR1, FGFR2 and FGFR3 genes cause premature fusion of the skull bones (craniosynostosis). We have investigated the patterns of expression of Fgfr1, Fgfr2 and Fgfr3 in the fetal mouse head, with specific reference to their relationship to cell proliferation and differentiation in the frontal and parietal bones and in the coronal suture. Fgfr2 is expressed only in proliferating osteoprogenitor cells; the onset of differentiation is preceded by down-regulation of Fgfr2 and up-regulation of Fgfr1. Following up-regulation of the differentiation marker osteopontin, Fgfr1, osteonectin and alkaline phosphatase are down-regulated, suggesting that they are involved in the osteogenic differentiation process but not in maintaining the differentiated state. Fgfr3 is expressed in the cranial cartilage, including a plate of cartilage underlying the coronal suture, as well as in osteogenic cells, suggesting a dual role in skull development. Subcutaneous insertion of FGF2-soaked beads onto the coronal suture on E15 resulted in up-regulation of osteopontin and Fgfr1 in the sutural mesenchyme, down-regulation of Fgfr2, and inhibition of cell proliferation. This pattern was observed at 6 and 24 hours after bead insertion, corresponding to the timing and duration of FGF2 diffusion from the beads. We suggest (a) that a gradient of FGF ligand, from high levels in the differentiated region to low levels in the environment of the osteogenic stem cells, modulates differential expression of Fgfr1 and Fgfr2, and (b) that signalling through FGFR2 regulates stem cell proliferation whereas signalling through FGFR1 regulates osteogenic differentiation.

Integrity signals

Registry

Crossref · 10.1242/dev.126.24.5611

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mutations in FGFR2 and FGFR3 tend to be highly localised, recurrent missense substitutions that encode gain-of-function proteins.

    “Mutations in FGFR2 and FGFR3 tend to encode highly localised, recurrent missense substitutions encoding proteins with gain-of-function properties.”

    From Craniosynostosis (2011) · cites this paper as [11]

  • The cellular consequences of FGFR2/FGFR3 mutation include enhanced proliferation, differentiation, and apoptosis of osteoblasts bordering the cranial suture mesenchyme; premature differentiation is probably the most important factor leading to craniosynostosis.

    “The cellular consequences of mutation are complex, including enhancement of proliferation, differentiation and apoptosis of osteoblasts bordering the cranial suture mesenchyme; premature differentiation is probably the most important factor leading to craniosynostosis.11,12”

    From Craniosynostosis (2011) · cites this paper as [11]

The citation lists haven’t been fetched yet

References 39 · Cited by 305

Authors
Iseki, S., Wilkie, A. O. M., & Morriss-Kay, G. M.
Affiliations
  • Tokyo Medical and Dental University (JP)
  • John Radcliffe Hospital (GB)
  • 1 Department of Human Anatomy and Genetics, South Parks Road, Oxford OX1 3QX, UK
Corresponding author
Iseki, S.
Venue
Development
Published
1999-12-15
Volume
126
Issue
24
Pages
5611-5620
ISSN
  • 0950-1991 (ISSN-L)
  • 1477-9129
OpenAlex
W2102230468
Cited by
305
References
39
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 10 · 2020: 12 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 9 · 2015: 6 · 2014: 10 · 2013: 11 · 2012: 7
FWCI
9.50
Type
journal article
Language
en
Open access
closed
Locations
  • Development (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wellcome Trust
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Craniofacial Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Keywords
FGFR1, FGFR2, FGFR3, fibroblast growth factor receptor, craniosynostosis, osteogenic differentiation, osteoprogenitor cells, cell proliferation, coronal suture, cranial cartilage, FGF2, osteopontin, alkaline phosphatase, SPARC, skeletal development
MeSH terms
Animals, Cell Differentiation, Cell Division, Mice, Inbred C57BL, Skull, Gene Expression, Receptors, Fibroblast Growth Factor, Receptor Protein-Tyrosine Kinases, Mice, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review